| FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis M Suker, BR Beumer, E Sadot, L Marthey, JE Faris, EA Mellon, ... The Lancet Oncology 17 (6), 801-810, 2016 | 919 | 2016 |
| Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial E Versteijne, M Suker, K Groothuis, JM Akkermans-Vogelaar, ... Journal of Clinical Oncology 38 (16), 1763-1773, 2020 | 828 | 2020 |
| Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial J Van Hilst, T de Rooij, K Bosscha, DJ Brinkman, S van Dieren, ... The lancet Gastroenterology & hepatology 4 (3), 199-207, 2019 | 524 | 2019 |
| Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial T de Rooij, J van Hilst, H van Santvoort, D Boerma, P van den Boezem, ... Annals of surgery 269 (1), 2-9, 2019 | 474 | 2019 |
| Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial E Versteijne, JL van Dam, M Suker, QP Janssen, K Groothuis, ... Journal of Clinical Oncology 40 (11), 1220-1230, 2022 | 359 | 2022 |
| Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ... JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019 | 290 | 2019 |
| The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a … MH Aziz, K Sideras, NA Aziz, K Mauff, R Haen, D Roos, L Saida, M Suker, ... Annals of surgery 270 (1), 139-146, 2019 | 237 | 2019 |
| Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III … G Van Tienhoven, E Versteijne, M Suker, KBC Groothuis, OR Busch, ... Journal of Clinical Oncology 36 (18_suppl), LBA4002-LBA4002, 2018 | 194 | 2018 |
| Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized … E Versteijne, CHJ van Eijck, CJA Punt, M Suker, AH Zwinderman, ... Trials 17, 1-8, 2016 | 159 | 2016 |
| Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib J Nonnekens, M van Kranenburg, CEMT Beerens, M Suker, M Doukas, ... Theranostics 6 (11), 1821, 2016 | 126 | 2016 |
| Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial) M Suker, JJ Nuyttens, FALM Eskens, BCM Haberkorn, PPLO Coene, ... EClinicalMedicine 17, 2019 | 47 | 2019 |
| Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial) J Van Hilst, EA Strating, T De Rooij, F Daams, S Festen, ... Journal of British Surgery 106 (7), 910-921, 2019 | 46 | 2019 |
| Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract JLA van Vugt, S Buettner, S Levolger, RRJ Coebergh van den Braak, ... PLoS One 12 (10), e0186547, 2017 | 46 | 2017 |
| Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial. CHJ Van Eijck, E Versteijne, M Suker, K Groothuis, MGH Besselink, ... Journal of Clinical Oncology 39 (15_suppl), 4016-4016, 2021 | 44 | 2021 |
| Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable … JC van Dongen, M Suker, E Versteijne, BA Bonsing, JSD Mieog, ... Annals of surgery 275 (5), 979-984, 2022 | 36 | 2022 |
| A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome MA Teriaca, M Loi, M Suker, F Eskens, CHJ van Eijck, JJ Nuyttens Radiotherapy and Oncology 155, 232-236, 2021 | 33 | 2021 |
| Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk M Loi, A Magallon-Baro, M Suker, C van Eijck, A Sharma, M Hoogeman, ... Radiotherapy and Oncology 134, 67-73, 2019 | 32 | 2019 |
| Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: Preliminary experience R Klaassen, A Steins, OJ Gurney‐Champion, MF Bijlsma, ... Molecular oncology 14 (9), 2176-2189, 2020 | 29 | 2020 |
| Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases M Suker, BG Koerkamp, PP Coene, E van der Harst, BA Bonsing, ... European Journal of Surgical Oncology 45 (10), 1906-1911, 2019 | 28 | 2019 |
| FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study M Suker, JJ Nuyttens, B Groot Koerkamp, FALM Eskens, CHJ van Eijck Journal of surgical oncology 118 (6), 1021-1026, 2018 | 24 | 2018 |
